source
- FDA delays review of Novo's hemophilia A drug denecimig over factory issuesUS regulators have extended the review of Novo's hemophilia A injection, denecimig, because of problems at an unnamed manufacturing facility. The FDA said ongoing remediation activities observed d…
- Diagnostic-driven therapies face patient loss due to workflow gaps, new commercialization model proposedThe sponsored article from Diaceutics highlights that while diagnostic-driven therapies are being developed faster than ever, many patients who could benefit never receive them. The authors attribu…